[go: up one dir, main page]

NO20076624L - Syklisk aminderivat med substituert alkylgruppe - Google Patents

Syklisk aminderivat med substituert alkylgruppe

Info

Publication number
NO20076624L
NO20076624L NO20076624A NO20076624A NO20076624L NO 20076624 L NO20076624 L NO 20076624L NO 20076624 A NO20076624 A NO 20076624A NO 20076624 A NO20076624 A NO 20076624A NO 20076624 L NO20076624 L NO 20076624L
Authority
NO
Norway
Prior art keywords
group
alkyl group
hydrogen atom
substituted alkyl
amine derivative
Prior art date
Application number
NO20076624A
Other languages
English (en)
Inventor
Tomio Kimura
Naoki Tanaka
Hiroyuki Kobayashi
Atsuhiro Sugidachi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of NO20076624L publication Critical patent/NO20076624L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet en forbindelse representert ved generell formel (I), et farmakologisk akseptabelt salt derav eller et prolegemiddel derav: I formelen betegner R1 et hydrogenatom, en eventuelt substituert Ci-C6~alkyl-gruppe, en eventuelt substituert C3-C6-sykloalkylgruppe eller lignende; R2 betegner et hydrogenatom, et halogenatom, en karboksygruppe, en C2-C7-alkoksy-karbonylgruppe, en karbamoylgruppe, en cyanogruppe, en Ci-C6-alkylgruppe, en halogen-Ci-C6-alkylgruppe, en C1-C6-alkylgruppe substituert med en hetero-arylgruppe eller lignende; R3 betegner en substituert Ci-C6-alkylgruppe, en heterosyklylgruppe eller en mono- til pentasubstituert heterosyklylgruppe; X1, X2, X3, X4 og X5 betegner uavhengig et hydrogenatom, et halogenatom, en aminogruppe, en karboksygruppe, en karbamoylgruppe, en cyanogruppe, en nitrogruppe, en Ci-C6-alkylgruppe eller lignende; og n betegner et helt tall på 0-2.
NO20076624A 2005-05-27 2007-12-21 Syklisk aminderivat med substituert alkylgruppe NO20076624L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005155009 2005-05-27
PCT/JP2006/310556 WO2006126676A1 (ja) 2005-05-27 2006-05-26 置換アルキル基を有する環状アミン誘導体

Publications (1)

Publication Number Publication Date
NO20076624L true NO20076624L (no) 2008-02-26

Family

ID=37452098

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076624A NO20076624L (no) 2005-05-27 2007-12-21 Syklisk aminderivat med substituert alkylgruppe

Country Status (13)

Country Link
EP (1) EP1889835A4 (no)
JP (1) JPWO2006126676A1 (no)
KR (1) KR20080013944A (no)
CN (1) CN101233108A (no)
AU (1) AU2006250335B2 (no)
BR (1) BRPI0610311A2 (no)
CA (1) CA2609852A1 (no)
IL (1) IL187524A0 (no)
NO (1) NO20076624L (no)
RU (1) RU2382771C2 (no)
TW (1) TW200720252A (no)
WO (1) WO2006126676A1 (no)
ZA (1) ZA200710172B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007001974A (ja) * 2005-05-27 2007-01-11 Sankyo Co Ltd ヘテロアリール環を有する環状アミン誘導体を含有する医薬組成物
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
WO2013168022A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
EP2852571A4 (en) 2012-05-23 2015-11-25 Cellix Bio Private Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
SG11201505283RA (en) * 2013-01-09 2015-08-28 Univ Michigan Mixed disulfide conjugates of thienopyridine compounds and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
SG11201702554QA (en) 2014-09-29 2017-04-27 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN107428697A (zh) 2015-01-06 2017-12-01 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3274088B2 (ja) * 1996-08-28 2002-04-15 三共株式会社 環状アミン誘導体
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
JP3856185B2 (ja) * 1998-02-27 2006-12-13 三共株式会社 環状アミノ化合物
JP3907029B2 (ja) * 1998-02-27 2007-04-18 三共株式会社 環状アミン誘導体を含有する医薬
CN100369896C (zh) * 1998-02-27 2008-02-20 三共株式会社 环胺化合物
RU2346935C2 (ru) * 2003-11-28 2009-02-20 Санкио Компани, Лимитед Производное циклического амина, содержащее гетероарильный цикл

Also Published As

Publication number Publication date
AU2006250335B2 (en) 2010-09-02
CA2609852A1 (en) 2006-11-30
AU2006250335A1 (en) 2006-11-30
BRPI0610311A2 (pt) 2010-06-15
WO2006126676A1 (ja) 2006-11-30
RU2382771C2 (ru) 2010-02-27
TW200720252A (en) 2007-06-01
IL187524A0 (en) 2008-03-20
RU2007149317A (ru) 2009-07-10
JPWO2006126676A1 (ja) 2008-12-25
EP1889835A1 (en) 2008-02-20
EP1889835A4 (en) 2010-04-28
ZA200710172B (en) 2008-11-26
KR20080013944A (ko) 2008-02-13
CN101233108A (zh) 2008-07-30

Similar Documents

Publication Publication Date Title
NO20076624L (no) Syklisk aminderivat med substituert alkylgruppe
NO20076010L (no) Heterosyklisk forbindelse
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20060142L (no) Syklisk tertiaer aminforbindelse
NO20084456L (no) Organiske forbindelser
NO20084302L (no) 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
NO20083582L (no) Pyridin-2-karboksamide derivater
RS53839B1 (en) SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1
NO341631B1 (no) Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
CY1112006T1 (el) Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c
EA200801381A1 (ru) Производные пиримидина
TN2010000091A1 (en) Substituted pyrazole derivative
MX2008014908A (es) Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo.
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20064077L (no) Kemokinreseptorantagonister
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
EA201000413A1 (ru) Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
WO2009095792A3 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
WO2008136444A1 (ja) 縮合複素環誘導体
NO20081169L (no) Nye camptothecinanalogforbindelser, en fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
WO2008155670A3 (en) Arylamide pyrimidone compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application